Suchergebnisse - "Kazandjian, Dickran"

PubPharm (8)

1

T cell redirecting bispecific antibodies for multiple myeloma : emerging therapeutic strategies in a changing treatment landscape

enthalten in: Leukemia & lymphoma | 2022

von Kazandjian, D. | Kowalski, A. | Landgren, O.

2

Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma : pooled analysis of four single-arm studies

enthalten in: Leukemia & lymphoma | 2022

von Landgren, O. | Kazandjian, D. | Roussel, M. | +7

3

Host-related immunodeficiency in the development of multiple myeloma

enthalten in: Leukemia & lymphoma | 2018

von Dosani, T. | Mailankody, S. | Korde, N. | +13

4

Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone

enthalten in: Leukemia & lymphoma | 2017

von Manasanch, E. | de Larrea, C. | Zingone, A. | +21

CommentIn: Leuk Lymphoma. 2017 Mar;58(3):513-515. - PMID 28093000

5

Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone

enthalten in: Leukemia & lymphoma | 2017

von Manasanch, E. | de Larrea, C. | Zingone, A. | +21

6

Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone

enthalten in: Leukemia & lymphoma | 2016

von Manasanch, E. | de Larrea, C. | Zingone, A. | +21

7

Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease : influence of biopsy site and anticoagulation method

enthalten in: Leukemia & lymphoma | 2015

von Manasanch, E. | Salem, D. | Yuan, C. | +15

8

Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method

enthalten in: Leukemia & lymphoma | 2015

von Manasanch, E. | Salem, D. | Yuan, C. | +15

1
[1]